Fluorescence-guided surgery uses near-infrared sensors to detect and display fluorescent biomarkers indicating the exact location of tumors. But the current cameras and monitors force surgeons to match the images to the body via subjective comparisons.

This long, error-prone process reduces the accuracy, and increases operating times and cost. This is a critical problem in cancer surgery where complete tumor removal is key to prevent a recurrence.

Arspectrac’s novel augmented reality glasses detect and display the fluorescent biomarkers in the surgeons’ direct sight, hence showing the tumor margins on the target.

The company’s innovation will increase surgeons’ accuracy and reduce tumor removal times. The EIC investment will help them finalise and validate their innovation’s technical developments and clinical usability according to end-user requirements.